Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Etonogestrel
Drug ID BADD_D00852
Description Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel.[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]
Indications and Usage Etonogestrel is administered in subdermal implants as long-acting reversible contraception. It is known to be effective in postpartum insertion including breastfeeding women.[A175990] Etonogestrel is part of the long-acting contraceptive implants that prevent pregnancy. The implant's effect can remain for 5 years.[L5698]
Marketing Status approved; investigational
ATC Code G03AC08
DrugBank ID DB00294
KEGG ID D04104
MeSH ID C044815
PubChem ID 6917715
TTD Drug ID D02KIU
NDC Product Code 64918-1500; 78206-145; 71161-147; 63190-0260; 45541-1192; 60870-0475; 63190-0480; 64918-1906; 65089-0053
UNII 304GTH6RNH
Synonyms etonogestrel | 13-ethyl-17-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one | 3-oxodesogestrel | 3-ketodesogestrel | 3-oxo desogestrel | 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)- | 3-keto-desogestrel | ORG-3236 | Implanon | nexplanon
Chemical Information
Molecular Formula C22H28O2
CAS Registry Number 54048-10-1
SMILES CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Implant site pain12.07.02.008; 08.02.02.0080.395143%Not Available
Pelvic discomfort21.10.01.012; 20.02.03.012; 07.01.06.0200.000517%Not Available
Complication of device insertion08.07.01.0020.800771%Not Available
Coital bleeding21.08.02.0150.002633%Not Available
Instillation site discomfort12.07.01.035; 08.02.01.0350.000517%Not Available
Application site scab23.03.03.050; 12.07.01.042; 08.02.01.0420.002797%Not Available
Adverse reaction08.06.01.0180.002868%Not Available
Type 1 diabetes mellitus14.06.01.010; 10.04.08.007; 05.06.01.0100.000235%Not Available
Vulvovaginal burning sensation21.08.02.0070.001316%Not Available
Skin mass23.07.04.0140.001199%Not Available
Intellectual disability19.21.06.001; 17.03.07.0010.000517%Not Available
Vulvovaginal pain21.08.02.0090.002797%
Abnormal withdrawal bleeding21.01.01.008; 08.06.02.0010.000635%Not Available
Injury associated with device12.01.08.035; 08.07.01.0120.015304%Not Available
Vulvovaginal erythema21.08.02.011; 23.03.06.0170.000799%Not Available
Vulvovaginal swelling21.08.02.0160.000799%Not Available
Functional gastrointestinal disorder07.11.01.0160.000517%Not Available
Application site haemorrhage24.07.01.048; 12.07.01.040; 08.02.01.0400.000799%Not Available
Adnexal torsion21.11.02.0120.000235%Not Available
Administration site discomfort12.07.04.010; 08.02.04.0100.005313%Not Available
Perforation08.01.03.0580.000799%Not Available
Complication associated with device08.07.01.0110.950140%Not Available
Frustration tolerance decreased19.04.02.0160.001316%Not Available
Blood blister12.01.06.013; 23.03.01.0280.000799%Not Available
Ovarian cyst ruptured21.11.01.015; 16.04.03.0060.000353%Not Available
Overweight14.03.02.0210.002868%Not Available
Placenta praevia18.05.02.0040.000353%Not Available
Post-traumatic stress disorder19.06.06.0020.000353%Not Available
Pulmonary artery stenosis24.04.09.011; 22.06.03.0060.000235%Not Available
Ruptured ectopic pregnancy18.02.02.0050.001175%Not Available
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 14 Pages